Metabolic Dysfunction-Associated Fatty Liver Disease Dynamics

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a unifying concept that links hepatic steatosis with systemic metabolic derangements. Unlike the earlier non-alcoholic fatty liver disease paradigm, MAFLD emphasises positive diagnostic criteria centred on metabolic dysfunction, thereby capturing a heterogeneous population at varying degrees of risk. Disease dynamics encompass the initiation, progression and potential regression of hepatic lipid accumulation under the influence of insulin resistance, adipose tissue dysregulation and inflammatory pathways. Clinically, MAFLD can present across a spectrum from simple steatosis to steatohepatitis, fibrosis and cirrhosis, with trajectories shaped by genetic predisposition, lifestyle factors and comorbid conditions such as type 2 diabetes and cardiovascular disease. Globally, prevalence estimates exceed 25 per cent of adults in some regions, imposing a mounting burden on healthcare systems. Understanding the interplay between metabolic drivers and liver pathology is crucial for stratifying risk, guiding surveillance and informing therapeutic interventions. Recent advances have focused on molecular mediators of lipotoxicity, the role of gut–liver axis perturbations and the prognostic value of non-invasive imaging and serum biomarkers. Integrating these insights into clinical practice holds promise for personalised management and for interrupting the adverse outcomes associated with advanced liver disease and systemic complications.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metabolic Dysfunction-Associated Fatty Liver Disease Dynamics publication trend

The graph below shows the total number of articles in metabolic dysfunction-associated fatty liver disease dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolic dysfunction-associated fatty liver disease (MAFLD): A liver disorder defined by hepatic fat accumulation in the presence of metabolic risk factors such as obesity, diabetes or dyslipidaemia.

Hepatic steatosis: Excessive triglyceride accumulation in hepatocytes, often visualised by imaging or histology.

Insulin resistance: Impaired cellular response to insulin signalling, leading to elevated blood glucose and dysregulated lipid metabolism.

Atherosclerosis: Progressive thickening and hardening of arterial walls due to lipid deposition and inflammatory cell infiltration.

Metabolic syndrome: A cluster of conditions—abdominal obesity, hypertension, hyperglycaemia, dyslipidaemia—that collectively increase cardiovascular and hepatic risk.

References

1. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study. Cardiovascular Diabetology (2023).
2. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. BMC Medicine (2023).
3. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology (2022).